Sharon Bell, RN
Clinical Trials Nurse
252-975-4308 ext. 104
Email: sbell@brhealthsystem.org
BREAST
Genetic Expression Profile (Duke University/Duke Institute for Genome Sciences & Policy)
A Randomized Phase II Trial Evaluating the Performance of Genomic Expression Profiles to Direct the Use of Preoperative Chemotherapy for Early Stage Breast Cancer
Primary Investigator – Jennie Crews, MD
Protocol Novartis CRAD001Y2301
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive, Locally Advanced or Metastatic Breast Cancer that is refractory to Letrozole or Anastrozole.
Primary Investigator – Jennie Crews, MD
ECOG E5103:
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Primary Investigator – Jennie Crews, MD
NCCTG N063D:
ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study: A Randomised, Multi-centre, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer
Primary Investigator: Jennie R. Crews, MD
CALGB 40502:
A Randomized Phase Iii Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone Combined with Bevacizumab as First -Line Therapy for Locally Recurrent or Metastatic Breast Cancer.
Primary Investigator: Jennie R. Crews, MD
Protocol Genentech TDM4370g
A Randomized, Multicenter, Phase III Open-Label Study of the Efficacy and Safety of Trastuzumab-MCC-DMI versus Capecitabine + Lapatinib in Patients with Her2 Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy
Primary Investigator – Jennie Crews, MD
LUNG
Protocol Amgen 20070782 Aranesp
A Randomized, Double-blind, placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500mcg Once-Every-3-Weeks in anemic subjects with advanced stage (wet IIIB) NSCLC receiving multi-cycle chemotherapy
Primary Investigator – John Inzerillo, MD
GASTROINTESTIONAL
LCCC 0918-COLON (UNC/LINEBERGER CANCER CENTER)
A Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Flourouracil in Patients Receiving FOLFOX6 With or Without Bevacizumab.
Primary Investigator – John Inzerillo, MD
CALGB 80405:
A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5FU/ Leucovorin with Bevacizumab or Cetuximab (C225) for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum.
Primary Investigator: Jennie R. Crews, MD
REGISTRY STUDY
Caris Diagnostics TCREG-001-00-V2-1209
A Registry of the Target Now® Test Results (Biomarker Expression Patterns) For Evaluation of Correlation with Clinical Outcomes for Cancer Patients.
Primary Investigator—Jennie R. Crews, MD
For general information about clinical trials visit www.cancer.gov/clinicaltrials/
